$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
乳腺癌新药阿贝西利在中国获批上市了吗?
2025-10-19 11:44:20
Check Details
乳腺癌新药卡培他滨多少钱一盒?怎么购买?
2025-10-19 11:44:20
Check Details
卡培他滨治疗晚期乳腺癌的效果分析及不良反应
2025-10-19 11:44:20
Check Details
新药卡培他滨治疗晚期乳腺癌的优势
2025-10-19 11:44:20
Check Details
卡培他滨联合紫杉醇治疗乳腺癌的疗效和安全性
2025-10-19 11:44:20
Check Details
卡培他滨可作为蒽环类和紫杉类治疗失败后的乳腺癌解救治疗
2025-10-19 11:44:20
Check Details
阿培利司+氟维司群显著延长分泌治疗失败激素受体阳性HER2阴性晚期乳腺癌生存期
2025-10-19 11:44:20
Check Details
阿贝西利治疗HR+/HER2-转移性乳腺癌有着较好的疗效
2025-10-19 11:44:20
Check Details
阿贝西利可有效提高HR+/EHR2乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
阿培利司的出现,使乳腺癌患者有了新选择!
2025-10-19 11:44:20
Check Details
患者使用阿培利司治疗乳腺癌时的注意事项
2025-10-19 11:44:20
Check Details
HR+/HER2-转移性乳腺癌克星药-阿贝西利
2025-10-19 11:44:20
Check Details
1
2
...
1987
1988
1989
1990
1991
1992
1993
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
2
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
7
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
8
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
9
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
10
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
11
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
12
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations